Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Generation Bio ( (GBIO) ) has issued an update.
On October 21, 2025, Generation Bio announced the resignation of Geoff McDonough as CEO, effective October 31, 2025. He will continue as Chairman of the Board. Yalonda Howze, previously the Chief Legal Officer, was appointed as Interim CEO and President. The company is undergoing a leadership transition amidst a strategic alternatives review process, with consulting agreements arranged for outgoing executives to ensure continuity.
The most recent analyst rating on (GBIO) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Generation Bio stock, see the GBIO Stock Forecast page.
Spark’s Take on GBIO Stock
According to Spark, TipRanks’ AI Analyst, GBIO is a Neutral.
Generation Bio’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and high leverage. While technical analysis shows some positive momentum, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on GBIO stock, click here.
More about Generation Bio
Generation Bio is a biotechnology company focused on developing redosable therapeutics to address T cell-driven autoimmune diseases. The company utilizes cell-targeted lipid nanoparticles (ctLNP) to deliver small interfering RNA (siRNA) to T cells, aiming to reprogram them and reduce the production of autoreactive T cells.
Average Trading Volume: 301,650
Technical Sentiment Signal: Sell
Current Market Cap: $42.5M
For a thorough assessment of GBIO stock, go to TipRanks’ Stock Analysis page.